TY - JOUR
T1 - The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant candida albicans
AU - Wiederhold, Nathan P.
AU - Najvar, Laura K.
AU - Fothergill, Annette W.
AU - McCarthy, Dora I.
AU - Bocanegra, Rosie
AU - Olivo, Marcos
AU - Kirkpatrick, William R.
AU - Everson, Michael P.
AU - Duncanson, Frederick P.
AU - Pattersona, Thomas F.
N1 - Publisher Copyright:
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandinresistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.
AB - The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandinresistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.
UR - https://www.scopus.com/pages/publications/84920202712
UR - https://www.scopus.com/pages/publications/84920202712#tab=citedBy
U2 - 10.1128/AAC.03944-14
DO - 10.1128/AAC.03944-14
M3 - Article
C2 - 25331706
AN - SCOPUS:84920202712
SN - 0066-4804
VL - 59
SP - 690
EP - 692
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 1
ER -